Detalhe da pesquisa
1.
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
N Engl J Med
; 370(19): 1781-9, 2014 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24806159
2.
Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Br J Clin Pharmacol
; 83(12): 2678-2686, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28722153
3.
Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.
Br J Clin Pharmacol
; 83(9): 1944-1953, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28345163
4.
Overcoming fragmentation of health research in Europe: lessons from COVID-19.
Lancet
; 395(10242): 1970-1971, 2020 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32559417
5.
Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Transpl Int
; 27(1): 77-86, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24164420
6.
First-in-Human, Single- and Multiple-Ascending-Dose, Food-Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy Subjects.
Clin Pharmacol Drug Dev
; 12(7): 749-760, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36860173
7.
Pharmacokinetics and Safety of Letermovir and Midazolam Coadministration in Healthy Subjects.
Clin Pharmacol Drug Dev
; 11(1): 16-24, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34714967
8.
The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 11(1): 6-15, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34812580
9.
Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
Clin Pharmacol Drug Dev
; 7(1): 9-21, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28967706
10.
The T cell-selective IL-2 mutant AIC284 mediates protection in a rat model of Multiple Sclerosis.
J Neuroimmunol
; 282: 63-72, 2015 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25903730
11.
AAA+ chaperones and acyldepsipeptides activate the ClpP protease via conformational control.
Nat Commun
; 6: 6320, 2015 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25695750
12.
Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism.
Nat Struct Mol Biol
; 17(4): 471-8, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20305655